120
Participants
Start Date
August 10, 2018
Primary Completion Date
October 12, 2021
Study Completion Date
July 12, 2023
Obinutuzumab
Administered via intravenous infusion
Bendamustine
Administered via intravenous infusion
Venetoclax
The venetoclax dose was administered according to a weekly ramp-up schedule over 5 weeks to the recommended daily dose of 400 mg. Venetoclax was continued for a total duration of up to 53 weeks, including the 5-week ramp-up schedule. Participants were instructed to take venetoclax tablets with a meal and water at approximately the same time each day. Venetoclax tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing.
Prisma Health Cancer Inst - Eastside /ID# 202329, Greenville
MidAmerica Division, Inc. /ID# 201099, Kansas City
Texas Oncology - Medical City Dallas /ID# 201196, Dallas
Texas Oncology - Northeast Texas /ID# 201211, Tyler
Texas Oncology - McAllen /ID# 202331, McAllen
Texas Oncology - Austin Midtown /ID# 201199, Austin
Rocky Mountain Cancer Centers - Denver Midtown /ID# 202328, Denver
Northwest Cancer Specialists, P.C. /ID# 201198, Vancouver
Arizona Oncology Associates, PC-HOPE /ID# 202335, Tempe
Oncology Hematology Care, Inc. /ID# 202397, Cincinnati
Willamette Valley Cancer Institute and Research Center /ID# 201201, Eugene
Tennessee Oncology - Chattanooga /ID# 202840, Chattanooga
Tennessee Oncology-Nashville Centennial /ID# 201098, Nashville
Texas Oncology - Beaumont /ID# 202359, Beaumont
Texas Oncology - San Antonio Medical Center /ID# 202332, San Antonio
Lead Sponsor
AbbVie
INDUSTRY